NZ786079A - Treatment of hidradenitis with jak inhibitors - Google Patents

Treatment of hidradenitis with jak inhibitors

Info

Publication number
NZ786079A
NZ786079A NZ786079A NZ78607920A NZ786079A NZ 786079 A NZ786079 A NZ 786079A NZ 786079 A NZ786079 A NZ 786079A NZ 78607920 A NZ78607920 A NZ 78607920A NZ 786079 A NZ786079 A NZ 786079A
Authority
NZ
New Zealand
Prior art keywords
subject
use according
hidradenitis suppurativa
hidradenitis
medicament
Prior art date
Application number
NZ786079A
Other versions
NZ786079B2 (en
Inventor
Dafydd Rhys Owen
Brian Stephen Gerstenberger
Andrew Fensome
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ786079A publication Critical patent/NZ786079A/en
Publication of NZ786079B2 publication Critical patent/NZ786079B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Methods for treating hidradenitis suppurtiva using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK). The compound is [(1S)-2,2-difluorocyclo-propyl][(1R,5S)-3-{ 2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl} -3,8-diazabicyclo[3.2.1]oct-8-yl]methanone.

Claims (8)

1. Use of [(1S)-2,2-difluorocyclo-propyl][(1R,5S){2-[(1-methyl-1H-pyrazol yl)amino]pyrimidinyl}-3,8-diazabicyclo[3.2.1]octyl]methanone, or a pharmaceutically 5 acceptable salt thereof, in the manufacture of a medicament for treating hidradenitis suppurativa in a human subject having lesions associated with hidradenitis suppurativa.
2. The use according to claim 1, wherein the treatment reduces inflammatory nodules, abscess and draining fistulas as measured by the subject’s HiSCR score.
3. The use according to claim 1, wherein the treatment reduces the median size of the subject’s hidradenitis suppurativa lesions.
4. The use according to claim 1, wherein the treatment increases the subject's time to 15 develop new hidradenitis suppurativa lesions.
5. Use of [(1S)-2,2-difluorocyclo-propyl][(1R,5S){2-[(1-methyl-1H-pyrazol yl)amino]pyrimidinyl}-3,8-diazabicyclo[3.2.1]octyl]methanone, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hidradenitis suppurtiva 20 in a human subject having lesions associated with hidradenitis suppurativa, wherein the medicament is to be administered to the subject in need thereof in an amount effective to treat a symptom of hidradenitis suppurativa in the subject.
6. The use according to claim 5, wherein said effective amount is about 0.01 to about 25 100 mg/kg of body weight/day, in a single dose or as divided doses administered two, three or four times per day.
7. The use according to claim 1, substantially as herein described with reference to any example thereof.
8. The use according to claim 5, substantially as herein described with reference to any example thereof.
NZ786079A 2020-09-08 Treatment of hidradenitis with jak inhibitors NZ786079B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962899133P 2019-09-11 2019-09-11
PCT/IB2020/058333 WO2021048736A1 (en) 2019-09-11 2020-09-08 Treatment of hidradenitis with jak inhibitors

Publications (2)

Publication Number Publication Date
NZ786079A true NZ786079A (en) 2025-10-31
NZ786079B2 NZ786079B2 (en) 2026-02-03

Family

ID=

Also Published As

Publication number Publication date
US12569487B2 (en) 2026-03-10
AR119942A1 (en) 2022-01-19
ES3019413T3 (en) 2025-05-20
TW202123940A (en) 2021-07-01
IL291146B1 (en) 2026-08-01
EP4028007A1 (en) 2022-07-20
JP2021042204A (en) 2021-03-18
CA3153676A1 (en) 2021-03-18
US20250032492A1 (en) 2025-01-30
IL291146A (en) 2022-05-01
BR112022004221A2 (en) 2022-05-31
KR20220059519A (en) 2022-05-10
CN114667148A (en) 2022-06-24
EP4028007B1 (en) 2025-03-26
WO2021048736A1 (en) 2021-03-18
AU2020347561A1 (en) 2022-04-14
TWI846947B (en) 2024-07-01
MX2022002995A (en) 2022-06-02
MX428336B (en) 2025-11-13
AU2020347561B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
HRP20240082T1 (en) Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
FI3157527T3 (en) Ezh2 inhibitors for treating lymphoma
JP2014515373A5 (en)
RU2013121788A (en) HIV REPLICATION INHIBITORS
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
RU2015102772A (en) Benzodiazelipas for small cell lung cancer
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2023003576A (en) Compound as akt kinase inhibitor.
BR112021025764A2 (en) Pyrimidine derivative that inhibits the growth of cancer cells and medicinal use thereof
JOP20210320A1 (en) Methods of treating cancer using prmt5 inhibitors
NZ595901A (en) Use of allopurinol for the treatment of hand foot skin reaction
JP2012525358A5 (en)
RU2014143213A (en) Tyrosine kinase inhibitor compounds and their use
NZ786079B2 (en) Treatment of hidradenitis with jak inhibitors
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
RU2012114097A (en) THERAPEUTIC AGENT AGAINST CHRONIC PAIN
HRP20191927T1 (en) THERAPEUTIC TREATMENT
AU2017299850A8 (en) Solid forms of TTK inhibitor
CN104147197A (en) Medicine for treating tinea pedis and preparation method thereof
CN105079555A (en) Medicine composition for treating myocardial ischemia
NZ743582A (en) Treatment of chronic hand eczema

Legal Events

Date Code Title Description
PSEA Patent sealed